Briefing on the Fundamentals of Lexaria Bioscience (LEXX)

Small-cap health care company Lexaria Bioscience has moved 16.6% this afternoon, reaching $0.86 per share. In contrast, the average analyst target price for the stock is $14.0.

Lexaria Bioscience Corp. operates as a biotechnology company. The company is based in Canada.

What to Consider if You Are Thinking of Buying Lexaria Bioscience:

  • Lexaria Bioscience has moved -65.6% over the last year.

  • LEXX has a forward P/E ratio of -1.0 based on its EPS guidance of -0.84.

  • Over the last 4 years, earnings per share (EPS) have been growing at a compounded average rate of 7.7%.

  • Its Price to Book (P/B) ratio is 1.03

Lexaria Bioscience Has Negative Cash Flows

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cashflow ($ k) YoY Growth (%)
2022-08-31 -4,879 -131 -5,011 -23.14
2021-08-31 -3,990 -79 -4,069 -50.88
2020-08-31 -2,663 -34 -2,697 28.55
2019-08-31 -3,006 -769 -3,775 n/a

Averaging $-3.89 Million over the last 4 years, Lexaria Bioscience has consistently negative free cash flows. Their compounded average growth rate over this period is -7.3%, and their coefficient of variability is 24.5%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.